Beyond the Coronavirus: China Pharma Market Set to Grow

Every news service globally is focused on COVID-19 (the “coronavirus”) and how it will affect the global population, but what of the Chinese health system itself? How does this sector operate during “normal” times? What will drive and restrain Chinese health markets?

These are some of the questions we have been looking at over the past 6 months.

Topics: Pharmaceuticals Industry Insights

Global Organ-on-Chips Market Worth $41.6 Million

Organ-on-chips (OOCs) are small plastic devices with biocompatible microfluid chambers containing multiple live human cells in a 3D culture that stimulate key physiological functions of body organs. The organ-on-chip market has grown 70.5% since 2015, reaching nearly $41.6 million in 2019, according to a report by The Business Research Company.

Topics: Biotechnology Pharmaceuticals Industry Insights

The Market Implications of the Coronavirus Outbreaks

Global stocks fell on Monday, with declines in all 11 sectors of the S&P 500, as concerns grew over the rising threat of the coronavirus.

Coronavirus outbreaks have disrupted global supply chains linked to China. According to The Wall Street Journal, some economists estimate that a prolonged Chinese shutdown could cost up to $1 trillion in lost manufacturing output.

Topics: Pharmaceuticals Healthcare Industry Insights

4 Top New Drugs That Will Make Their Mark in the Coming Years

Every year several new drugs enter the pharma value chain. The launch of a new therapy or drug means a new treatment option for the patient pool and advancement in people’s quality of life.

Topics: Pharmaceuticals Industry Insights

Pharmaceutical Packaging Industry: Forecasts and Analysis

The demand for global pharmaceutical packaging reached an estimated $94.2 billion in 2018, according to new research and analysis from The Freedonia Group’s comprehensive study Global Pharmaceutical Packaging.

Topics: Pharmaceuticals Industry Insights The Freedonia Group

Cold Chain Logistics: A Fast Growing Segment of the Biopharmaceutical Logistics Market

According to a report from The Business Research Company, the cold chain logistics market, which moves biologics, is growing faster globally than the non-cold-chain logistics market, which transports small molecule drugs. Between 2012 and 2018, the cold-chain logistics market more than doubled in size, while the non-cold-chain logistics market grew by only 36% in comparison.

Topics: Pharmaceuticals Transportation & Shipping Industry Insights

China Bioprocessing Equipment Strategy & GMP Quality Management Drives Increased Need for Staffing, Expertise

According to Advances in Biopharmaceutical Technology in China, 2nd Ed, a report from BioPlan Associates, China is making strides in raising its Good Manufacturing Process (GMP) standards as it works to improve its global profile. GMP biopharmaceutical manufacturing has a short history in China, with the first version of guidance issued in 1998. In 2010, China's Ministry of Health released its fourth version of China GMP, with this iteration significantly raising the standards to be met by domestic biopharmaceutical developers.

Topics: Biotechnology Pharmaceuticals Industry Insights

Top 9 Things to Know About the Weight Loss Industry

The total U.S. weight loss industry hit a new peak in 2018, growing 4% to $72 billion. The largest diet companies are shifting direction and changing ownership as Weight Watchers rebrands itself to its new name WW and focuses more on wellness, Jenny Craig is up for sale, NutriSystem gets acquired by Tivity Health, and Slim-Fast is acquired by Glanbia, a multilevel marketing firm.

Topics: Food & Beverage Pharmaceuticals Healthcare

Can China Become a Top Destination for Biologics Manufacturing?

Many have questioned whether China can move from "the world's factory” for consumer goods, electronics, and commodities, into technologically complex biologics.

Topics: Biotechnology Pharmaceuticals Industry Insights

China Biopharmaceutical Growth Exceeding Western Projections

It shouldn’t come as a surprise that biopharma in China is growing faster than many in the West have projected. A number of economic and development factors are contributing to this growth. But these have all been evolving for decades. 

So if there is a gap in Western (and in some cases China’s own internal) knowledge about this evolution, it should be put down to simply not paying enough attention.  

Topics: Biotechnology Pharmaceuticals Industry Insights